Bleeding, Thrombosis and Vascular Biology (Jun 2023)

Management of anticoagulation in atrial fibrillation patients in Italy: insight from the <i>Atrial Fibrillation-Survey on Anticoagulated Patients Register</i> (AF-START)

  • Daniela Poli,
  • Walter Ageno,
  • Emilia Antonucci,
  • Salvatore Bradamante,
  • Eugenio Bucherini,
  • Paolo Chiarugi,
  • Antonio Chistolini,
  • Benilde Cosmi,
  • Anna Falanga,
  • Antonio Insana,
  • Domenico Lione,
  • Rosa Maria Lombardi,
  • Giuseppe Malcangi,
  • Rossella Marcucci,
  • Giuliana Martini,
  • Lucilla Masciocco,
  • Carmelo Paparo,
  • Daniele Pastori,
  • Simona Pedrini,
  • Vittorio Pengo,
  • Pasquale Pignatelli,
  • Andrea Toma,
  • Sophie Testa,
  • Gualtiero Palareti

DOI
https://doi.org/10.4081/btvb.2023.84
Journal volume & issue
Vol. 2, no. 2

Abstract

Read online

The survey on anticoagulated patients register (START-Register) is an independent, prospective, inception-cohort observational study aimed at providing information on patients on vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) in Italy. In this study, we describe the cohort of atrial fibrillation (AF) patients in the START-Register and report outcomes and changes in anticoagulant prescription from 2011 to 2021. The study included 11,078 AF patients, enrolled in 47 Italian centers distributed all over the Country; the median age was 77 years (range 18-99 years); 6029 (54.3%) were men; 5135 (46.4%) were on VKAs, and 5943 (53.6%) were on DOACs. Warfarin was the most prescribed VKA (98.4%), and apixaban was the most prescribed DOAC (31.6%). Among DOAC users, 4022 (67.7%) patients were naive to anticoagulation, and 2562 (43.1%) patients were treated with a reduced dose. DOAC patients were significantly older than VKA patients (median age 79 years vs 76 years respectively, P<0.001), but no gender difference was detected. The mean CHA2DS2VASc score was higher in DOAC users than in VKA users (3.7 vs 3.6; P=0.03). The mean HAS-BLED score was not different between the two groups. During follow-up, 542 bleeding events were recorded [2.44 per 100 patient-years (pt-yrs)]; 240 were major (1.08 per 100 pt-yrs), and 301 were clinically relevant non-major bleedings (1.34 per 100 pt-yrs). 146 thrombotic events were recorded during follow-up (0.66 per 100 pt-yrs). The total mortality rate was 3.5 per 100 pt-yrs; the mortality rate was 4.54 per 100 pt-yrs among patients on VKAs and 2.31 per 100 pt-yrs among patients on DOACs. During the last 10 years, in Italy, AF patient management has changed with the large spread of DOACs all over the Country. DOAC patients are frequently treated with reduced doses and show a lower mortality rate in comparison to patients on VKAs.

Keywords